These studies each demonstrate evidence that imaging modalities such as MRI and tau binding radioligands (F-AV-1451) can accurately differentiate between PD and PSP disease states, and even between PSP subtypes. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.